<DOC>
	<DOC>NCT01855490</DOC>
	<brief_summary>The study is designed as an open labeled pilot trial to analyze the acute responses of glucose, GLP-1, GIP, insulin secretory,and glucagon to a mixed meal tolerance test (MMTT) or intravenous glucose tolerance tests (IVGTT) with and without pretreatment with Exenatide (Byetta) 5 mcg sc. The investigators will also test the effects of Exenatide on gastric emptying during the MMTT.</brief_summary>
	<brief_title>Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>T1D of at least 3 yrs duration. Male or female aged 1856 years who meets the American Diabetes Association standard T1DM criteria. HgbA1c&lt;9% Insulin requirement of &lt; 0.8 U/kg/d Absence of severe hypoglycemia in the past 6 months Absence of ketoacidosis in the past 6 months Menstruating women must have a negative pregnancy test and be willing to avoid pregnancy during the study period. Signed informed consent.. Inability or unwillingness to give informed consent. Prior Exenatide or Liraglutide treatment or use of any medication that could potentially affect diabetes or immunologic status Known hypersensitivity to Exenatide or any product components Participation in an investigational treatment trial within the last 6 weeks before enrollment. Any medical condition that in the opinion of the investigator would interfere with safe completion of the trial such as: epilepsy, atopic disease, active Grave's disease, cystic fibrosis, sickle cell anemia, neuropathy, peripheral vascular disease, cerebrovascular disease,liver disease, HIV, or any concurrent autoimmune disease except treated and stable thyroid disease Known severe renal impairment, endstage renal disease or renal transplantation. Any history of gastroparesis or other severe gastrointestinal disease, pancreatitis, thyroid nodules or malignancy with the exclusion of a history of localized basal cell carcinoma. Uncompensated heart failure, fluid overload, myocardial infarction or liver disease within the last 6 weeks before enrollment. Active clinically serious infections. Positive pregnancy test in menstruating women or lactating females</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>